G6PDi-1 B

CAS No. 2457232-14-1

G6PDi-1 B( —— )

Catalog No. M37586 CAS No. 2457232-14-1

G6PDi-1 is an effective G6PD inhibitor. It depletes NADPH and decreases inflammatory cytokine production.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 Get Quote
5MG 76 Get Quote
10MG 132 Get Quote
25MG 266 Get Quote
50MG 426 Get Quote
100MG 614 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    G6PDi-1 B
  • Note
    Research use only, not for human use.
  • Brief Description
    G6PDi-1 is an effective G6PD inhibitor. It depletes NADPH and decreases inflammatory cytokine production.
  • Description
    G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50?of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2457232-14-1
  • Formula Weight
    284.34
  • Molecular Formula
    C14H12N4OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (175.85 mM; Ultrasonic )
  • SMILES
    O=C1CCCCc2nc(Nc3csc(c3)C#N)ncc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jonathan M Ghergurovich, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat Chem Biol. 2020 Jul;16(7):731-739.?
molnova catalog
related products
  • G6PDi-1

    G6PDi-1 is an effective G6PD inhibitor. It depletes NADPH and decreases inflammatory cytokine production. G6PDi-1 effectively inhibits G6PD.?

  • AGI-14100

    AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.

  • IMB-XMA0038

    IMB-XMA0038 is a novel inhibitor targeting Mycobacterium tuberculosis aspartate semialdehyde dehydrogenase with antimicrobial activity for use in tuberculosis research.